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Hypofractionated Stereotactic Radiotherapy 
for Primary and Secondary Intrapulmonary Tumors 
First Results of a Phase I/II Study 
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Purpose: To evaluate the feasibility, efficacy, and side effects of dose escalation in hypofractionated stereotactic radiotherapy 
(hfSRT) for intrapulmonary tumors with the Novalis™ system (BrainLAB AG, Heimstetten, Germany). 
Patients and Methods: From 07/2003 to 01/2005, 21 patients/39 tumors were treated with 5 × 7 Gy (n = 21; total dose 35 Gy) 
or 5 × 8 Gy (n = 18; total dose 40 Gy). There were three cases of primary lung cancer, the remainder were metastases. Median 
gross tumor volume (GTV) and planning target volume (PTV) were 2.89 cm3 (range, 0.15–67.94 cm3) and 25.75 cm3 (range, 
7.18–124.04 cm3), respectively. 
Results: Rates of complete remission, partial remission, no change, and progressive disease were 51%, 33%, 3%, and 13%, 
respectively. No grade 4 toxicity occurred, nearly all patients had grade 1 initially. One grade 3 toxicity, i.e., dyspnea, was docu-
mented for a period of 6 months after therapy. Radiosurgery quality assurance guidelines could be met. 
Conclusion: hfSRT of primary and secondary lung tumors using a schedule of five fractions at 7–8 Gy each was well tolerated. 
Further dose escalation is planned. 
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Hypofraktionierte stereotaktische Radiotherapie primärer und sekundärer Lungentumoren. Präliminäre Ergebnisse 
einer Phase-I/II-Studie 
Ziel: Auswertung der Durchführbarkeit, Wirksamkeit und Nebenwirkungen einer Phase-I/II-Studie zur Dosiseskalation bei hy-
pofraktionierter stereotaktischer Radiotherapie (hfSRT) von Lungentumoren mit dem Novalis™-System (BrainLAB AG, Heim-
stetten). 
Patienten und Methodik: 21 Patienten/39 Tumoren wurden von Juli 2003 bis Januar 2005 mit 5 × 7 Gy (n = 21; Gesamtdosis 
[GD] 35 Gy) oder 5 × 8 Gy (n = 18; GD 40 Gy) bestrahlt. Drei Patienten hatten ein primäres Lungenkarzinom, die übrigen Metasta-
sen. Das mediane „gross tumor volume“ (GTV) und Planungszielvolumen (PTV) betrugen 2,89 cm3 (0,15–67,94 cm3) und 25,75 cm3 
(7,18–124,04 cm3). 
Ergebnisse: Eine komplette Remission, partielle Remission, keine Änderung und Progression fanden sich bei 51%, 33%, 3% und 
13%. Nach initialer Grad-1-Toxizität in fast allen Fälle trat keine Grad-4-Toxizität auf. Eine Patientin erlitt eine Grad-3-Toxizität. 
Die RTOG-Qualitätskriterien für die Radiochirurgie wurden bei allen Patienten erfüllt. 
Schlussfolgerung: Die hfSRT mit 5 × 7 Gy und 5 × 8 Gy wurde gut vertragen. Die Dosiseskalation wird fortgeführt. 
Schlüsselwörter:  Hypofraktionierte stereotaktische Radiotherapie · Lungentumoren · Novalis™-System 
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Introduction
Stereotactic radiotherapy and radiosurgery (SRS) is well es-
tablished for the treatment of brain tumors [5, 13, 15]. Given 
the ability to perform stereotactic radiosurgery and fraction-
ated stereotactic treatment with the Novalis™ system (Brain-
LAB AG, Heimstetten, Germany), we decided to translate 
the technique into body stereotactic treatment. Extracranial 
stereotactic radiotherapy (ESRT) has demonstrated high ef-
ficacy and a low rate of side effects [4, 32, 36, 38]. Hypofrac-
tionation, from a radiobiological point of view, may yield 
significant benefits over using a single high-dose radiosur-
gery by opening up a therapeutic window between tumor 
control and late effects. This paradigm holds especially true 
for malignant tumors [10, 26]. However, the optimal single 
and total dose have yet to be defined. In this paper, early re-
sults including toxicity of a phase I/II study of hypofraction-
ated stereotactic radiotherapy (hfSRT) for intrapulmonary 
tumors are given. 
Patients and Methods 
Eligibility and Process of Dose Escalation 
Treatment protocol and consent form were approved by an 
institutional review board and ethic’s committee of the Uni-
versity of Erlangen, Germany. All patients were required to 
be medically inoperable or not eligible for surgery due to un-
favorable tumor location as indicated by an experienced tho-
racic surgeon. Patients with stage I non-small cell lung cancer 
(NSCLC), i.e., T1 or T2 N0 M0, were accepted, if the gross 
tumor volume (GTV) had a diameter of ≤ 7 cm (existing data 
for hfSRT of lung cancer [31]). Second indication were pa-
tients with oligometastatic disease (up to four metastases, 
each of them not > 4 cm, one single metastasis not > 7 cm in 
diameter). No exclusion criteria for FEV1 (forced expiratory 
volume in 1 s) were defined, because hfSRT was the only al-
ternative treatment to surgery. First dose level was 5 × 7 Gy 
(90% isodose). Patient groups in the subsequent levels re-
ceived an additional 1 Gy per fraction. Fractions were sepa-
rated by an interval of 2 days. Overall treatment time was 10 
days, including the weekend pause. A minimum of three pa-
tients should be assigned to each dose level. Toxicity was grad-
ed according to the Common Toxicity Criteria (CTC) [27]. 
Dose-limiting toxicity (DLT) was defined as any grade 3/4 
pulmonary, esophageal, cardiac, or spinal toxicity. If two or 
more patients experienced DLT, the maximum tolerable dose 
(MTD) would be reached. If DLT occurred in one patient, 
another two for the same dose level would be enrolled. Pro-
ceeding to the next dose level without DLT in these two pa-
tients would be possible after a minimum observation period 
of 12 weeks after treatment.
Patient and Tumor Characteristics
21 patients were entered (07/2003–01/2005), median age 54 
years (range, 18–75 years), Karnofsky performance status 80 
(range, 70–100). Further characteristics are given in Table 1. 
FEV1 < 40% was present in three patients (one third required 
home oxygen therapy before hfSRT). 
Treatment Planning, Immobilization, and 
Radiation Delivery 
All patients were immobilized in supine position, with a 
self-constructed abdominal press with three plungers, one 
anterior and two on each flank (Figure 1). Helical CT images 
(3 mm, SomatomPlus4, Siemens, Erlangen, Germany) were 
obtained in deep inspiration breath hold (room lasers marked 
on the skin and three fiducial markers positioned). Solid tu-
mor with blurred margin was considered to be GTV. Clinical 
target volume (CTV) was GTV without margin. Planning 
target volume (PTV), as to include setup inaccuracies and 
potential tumor movement, was the expansion of GTV plus 
5, 5, and 10 mm in x-, y-, and z-directions, respectively. Plan-
ning was performed with Novalis™ Brain Scan treat-
ment-planning system (Version 5.31, BrainLAB AG). All 
isocenters were marked by the use of laser lines on the skin 
Table 1. Patient and tumor characteristics. GTV: gross tumor volume; 
PTV: planning target volume. 
Tabelle 1. Patienten- und Tumorcharakteristika. GTV: „gross tumor 
volume“; PTV: Planungszielvolumen. 
 Patients  (n)
Age (years)
Median 54
Range 18–75
Gender
Male     8
Female 13
Histology (39 tumors) 
Lung cancer
• Adenocarcinoma    8
• Squamous cell carcinoma    1
Thyroid cancer
• Follicular  12 
Breast cancer    4
Rectal cancer    8
Cervical carcinoma    2
Ewing’s sarcoma    3
Leiomyosarcoma    1
Tumor side
Right lung  18
Left lung  21
Tumor location
With ≤ 2 cm distance to basal pleura    4
With ≤ 2 cm distance to medial pleura  13
With ≤ 2 cm distance to lateral pleura  14
Central     8
Treatment volumes [cm3, median (range)]
GTV    2.89 (0.15–67.94)
PTV 25.75  (7.18–124.04)
Dose level
5 × 7 Gy  21 lesions
5 × 8 Gy  18 lesionsErnst-Stecken A, et al. hfSRT for Intrapulmonary Tumors
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at our treatment simulation X-ray unit (Simulix-HQ, Nucle-
tron, Veneridaal, The Netherlands). Radiation was delivered 
using a median number of three beams (range, one to six 
beams). In 38 cases, dynamic conformal arc technique was 
performed, in one case static conformal beams were used. 
Dose calculation was done by pencil beam algorithm. The 
treatment delivery Novalis™/ExacTrac™ system (BrainLAB 
AG) has been described before [7]. ExacTrac™ is intended to 
place patients at the isocenter of a linear accelerator. It uses 
stereoscopic X-ray registration of two radiographs, X-ray fu-
sion with the DRR (digitally reconstructed radiograph), and 
automatic positioning correction. 
Quality Criteria and Evaluation 
According to the RTOG guidelines [28] for radiosurgery dose 
homogeneity, conformation and 90% isodose coverage for 
90% of the PTV were required. Dmin and Dmax were docu-
mented. 
Follow-up and Statistics 
We evaluated the quality of hfSRT using the aforementioned 
quality criteria and response after hfSRT with CT imaging 8 
weeks after the end of hfSRT and every 3 months thereafter. 
Treatment-related side effects were documented according to 
the CTC scoring system. 
Results 
Local Tumor Control and Survival 
Complete response (CR), partial response (PR), no change 
(NC), and progressive disease (PD) were seen in 51%, 33%, 
3%, and 13%, respectively. This resulted in an overall response 
rate of 87% (no statistically significant difference between dose 
levels). Median follow-up was 6.3 months (range, 1–21 months). 
Four local relapses occurred after 8, 9 (two lesions), and 13 
months. Eight patients (38%) live with no evidence of disease, 
three are alive with progressive disease, six with new lung me-
tastases, one with local control and extrapulmonary progressive 
disease, three died of local progressive disease (follow-up 1.4 
months), extrapulmonary disease (follow-up 9 months) and 
other reasons (follow-up 2.3 months). Follow-up for patients 
without progression was 1–21 months (median 6.4 months). 
Local control was not associated with histology. 
Typical Follow-up Imaging Study 
The typical appearance of a treated tumor showing minimal 
change of normal lung tissue together with tumor shrinkage is 
demonstrated in Figure 2. 
Quality Criteria 
With the Novalis™ system, all of the RTOG quality criteria 
were met: median homogeneity index 1.16 (range, 1.02–1.36), 
median conformity index 1.29 (range, 1.12–1.98), and median 
coverage 97.8% (range, 86.6–100%). Median maximum dose   
was 115% (range, 102–136%), and medium minimum dose 
88% (range, 70–100%).
Organs at Risk and Clinical Outcome 
Follow-up pulmonary function tests (PFTs) were only per-
formed in the three patients with FEV1 < 40%. PFTs remained 
stable throughout the observation period. Grade 1 clinical 
side effects occurred in nearly all patients for up to 0.5 years, 
radiologic side effects for up to 1 year after treatment. No grade 
Figure 1a – Abbildung 1a 
Figures 1a and 1b. Patient setup with abdominal press. Treatment plan-
ning with CT scan (a), setup at the linear accelerator (b). Arrow show-
ing the individual and marked impression by the abdominal press. 
Abbildungen 1a und 1b. Patientenlagerung mit Bauchpresse. Lagerung 
bei der Computertomographie (a) und bei der Bestrahlung (b). Der 
Pfeil zeigt die individuell angepasste Imprimierung durch die Bauch-
presse. 
➞
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2 pulmonary toxicity was seen. One patient (dose level 1) ex-
perienced grade 3 toxicity (dyspnea at rest, Table 2). This re-
solved with steroids after 0.5 years. Dose-volume histograms 
(DVHs) of normal lung tissue were documented. With 18 
right-sided and 21 left-sided tumors, the following values 
were drawn from the DVHs: left lung: a median total volume 
of 180 cm3 (range, 0–730 cm3) was irradiated with > 2 Gy, 
77.5 cm3 (range, 0–250 cm3) with > 4 Gy, and 42.5 cm3 (range, 
0–140 cm3) with > 6 Gy, respectively; right lung: a median to-
tal volume of 110 cm3 (range, 0–670 cm3) was irradiated with 
Figure 2c – Abbildung 2c             Figure 2d – Abbildung 2d 
Figure 2a – Abbildung 2a             Figure 2b – Abbildung 2b 
Figures 2a to 2e. Case follow-up study. Treatment planning (a), three dynamic conformal arcs; follow-up at 6 months (b), 9 months (c), 12 months 
(d) and 15 months (e). Arrows showing the residual tumor (b) and the normal-tissue reactions (e) (continued next page). 
Abbildungen 2a bis 2e. Fallbeispiel. Isodosenverläufe (a), drei dynamische Rotationen; Nachuntersuchung nach 6 Monaten (b), 9 Monaten (c), 
12 Monaten (d) und 15 Monaten (e). Die Pfeile zeigen den Resttumor (b) und die Fibrose (e) (Fortsetzung s. nächste Seite). 
➞  
➞  
➞  
➞
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> 2 Gy, 30 cm3 (range, 0–305 cm3) with > 4 Gy, and 20 cm3 
(range, 0–180 cm3) with > 6 Gy, respectively. 
Discussion 
Rationale for Extracranial Stereotactic Radiotherapy 
(ESRT) 
Surgical resection remains the treatment of choice for patients 
with NSCLC stage I. However, there exists a large medically 
inoperable subgroup. Older studies revealed that 15% of these 
patients are long-term survivors, about 
25% die of intercurrent disease, 30% of 
distant metastatic disease, and a signifi-
cant percentage of 30% die after local 
failure only, respectively [29]. Regional 
failure only occurs in not more than 
about 7% of all stage I NSCLC patients 
[30]. Thus, elective node irradiation is 
not necessary. Patients with their prima-
ry controlled had a cause-specific sur-
vival at 5 years four times higher than 
those with uncontrolled primary (46% 
vs. 12%; p = 0.03) [30]. Retrospective 
data showed a trend toward improved 
cause-specific survival with higher radio-
therapy doses. This emphasizes the need 
for dose-escalation studies. Belderbos et 
al. achieved nearly 90% overall response 
rate (CR and PR) in 50 patients treated 
with a total dose of 74.3 or 81.0 Gy with 
2.25 Gy per fraction. DLT was not 
reached at the last dose level [2]. How-
ever, until now, complete results of tox-
icity except esophagitis have not been published yet [1]. SRS 
and hfSRT today have been expanded to extracranial targets 
[3, 22, 33, 36]. Tumor control rates up to 85–97% have been 
reached which can compete with the best surgical series (Ta-
ble 3) [21]. Systematic lymph node dissection in T1 and T2 tu-
mors may no longer be essential due to staging with positron 
emission tomography. So, for the future, both modalities 
should be considered also with regard to low side effects after 
ESRT and low costs. Besides stage I NSCLC patients, a large 
proportion of our patient group were those with a finite num-
ber (one to four) of metastases (oligometastatic disease). 
From literature reviews, we know that these patients may ex-
perience improved survival by resection of their metastases 
and the primary site [6, 12]. 
Figure 2e – Abbildung 2e
Table 2. Toxicity (CTC [Common Toxicity Criteria] Score). 
Tabelle 2. Toxizität (CTC-Score [Common Toxicity Criteria]). 
Follow-up time (months)    2    5    8  11  14  17
At risk  39  32  13  11    8    8
Grade 1  30  32    7    2    0    0
Grade 2    0    0    0    0    0    0
Grade 3    1    1    0    0    0    0
Grade 4    0    0    0    0    0    0
Table 3. Review of literature. LC: local control; NSCLC: non-small cell lung cancer. 
Tabelle 3. Literaturüberblick. LC: lokale Kontrolle; NSCLC: nichtkleinzelliges Bronchialkarzinom.
Authors/year   Indications  Dose concept  LC  LC
   (dose  specification)  (NSCLC)  (metastases)
Blomgren et al. 1995   Metastases  3 × 10 – 2 × 15 Gy,   3/3  13/14
[3] NSCLC  65%  isodose  100%  93% 
Uematsu et al. 1998   Metastases  5–15 fx, 30–76 Gy,   22/23  42/43
[33] NSCLC  80%  isodose  96%  98% 
Uematsu et al. 2001   NSCLC  5–10 fx, 50–60 Gy,    47/50  –
[34]     100% isodose,  96%  – 
   80%  coverage   
Nagata et al. 2002   Metastases  4 × 10–12 Gy,   31/33  31/33
[23] NSCLC  100%  isodose  94%  94% 
Onimaru et al. 2003   Metastases  8 fx, 40–60 Gy,   20/25  18/20
[25] NSCLC  80–100%  isodose  80%  90% 
Lee et al. 2003   Metastases  3–4 × 10 Gy,   8/9  23/25
[20] NSCLC  90%  isodose  89%  92% 
Timmerman et al. 2003   NSCLC  3 × 8 – 3 × 20 Gy,   31/37
[31]    80% isodose  84%,  
      no relapse ≥ 18 Gy 
This study  NSCLC  5 × 7–8 Gy,   3/3  31/36
   90%  isodose  100%  86% 
Figures 2a to 2e (continued). Case follow-up study. Follow-up at 15 
months (e).  
Abbildungen 2a bis 2e (Fortsetzung). Fallbeispiel. Nachuntersuchung 
nach 15 Monaten (e). 
➞  Ernst-Stecken A, et al. hfSRT for Intrapulmonary Tumors
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Patient Setup Accuracy 
The following prerequisites have to be met for high setup ac-
curacy: reliable immobilization, reduction of organ motion, 
and quick radiation delivery. Different fixation methods for 
patients are used. A system using a stereotactic body frame 
with integrated vacuum pillow revealed positioning errors in 
all directions of up to 5 mm and target setup deviations of up 
to 10 mm [14, 19, 24]. Since the Novalis™ system allows for the 
control of deviations as related to bony structures in all six 
planes, i.e., translational and rotational directions, there is no 
necessity of correctly positioning a frame around the patient 
as the bony landmarks themselves are positioned. X-ray veri-
fication with ExacTrac™ revealed a setup accuracy within 
1 mm in all directions for all patients. In addition, abdominal 
pressure devices may significantly reduce organ movements 
[14, 19, 33]. Therefore, a home-built abdominal press was im-
plemented into our system (Figure 1). We applied as much 
pressure as could be tolerated without any side effects. How-
ever, even with abdominal pressure, breathing mobility re-
mains the major factor for setup inaccuracy, especially for 
lesions close to the diaphragm [16].
Dose Prescription, Planning Algorithm, 
and Radiation Dose Delivery 
According to literature data, using SRS techniques, lung tu-
mors are being treated with two to eight fractions of 5–20 Gy 
each. Although overall response rates varied in an only small 
range between 80% and 100% [3, 20, 23, 25, 31, 33], a com-
parison of the results remains difficult because of different 
total dose and variations in dose prescription. According to 
the existing data, dose was being prescribed to the 65–100% 
isodose and there is no evidence, that an increased inhomoge-
neity inside the target volume may be followed by higher re-
sponse rates (Table 3). As an admission to the guidelines for 
cranial radiosurgery, we would recommend to meet the re-
quirements for homogeneity, coverage and conformity [28] in 
order to better compare the future results. 
Another problem is the lack of detailed information on 
the calculation models that are used. It is well known for 
low-density lung tissue, that simple calculation models like 
pencil beam algorithm in contrast to collapsed cone and Mon-
te Carlo algorithm may overestimate the amount of absorbed 
dose up to 20% at the interface between tumor and lung tis-
sue. Several studies have proven this effect especially for pre-
scription of the dose to the edge of the target, for small targets 
with a PTV ≤ 100 cm3 and the use of high-energy, i.e., 18-MeV, 
photons [9, 17, 18] as compared to low-energy photons. Con-
sequently, the more reliable collapsed cone algorithm should 
be used in future trials. 
The majority of our patients were treated by dynamic 
conformal arcs guaranteeing a maximum of dose conformity. 
Furthermore, it is reasonable to disperse the dose outside the 
target volume over large areas and reduce the lung volumes 
receiving high doses. Willner et al. [35] showed that reducing 
the high-dose volume will result in a lower pneumonitis rate 
as compared to a reduction of lung volumes receiving low 
dose.
Response Rates and Toxicity 
Until now, a number of well-conducted studies revealed re-
markably good results following fractionated stereotactic 
treatment of early lung cancer (Table 3). Few data, however, 
exist on toxicity after hfSRT of lung tumors: acute grade 1 tox-
icity was documented in 5–9% of patients [33], and grade 2 
toxicity in 4% of patients [11, 25], respectively. Severe side 
effects were only reported occasionally [3, 25]. Our data com-
pare very favorably with these results. Nevertheless, four pa-
tients relapsed in this series up to 13 months after treatment, 
even after 5 × 8 Gy. Timmerman et al. [31] saw no recurrences 
when treating patients with doses > 3 × 18 Gy. Using the sim-
ple calculation model given by Fowler [8] assuming an α/β-val-
ue of 10 Gy for malignant tumors, the two aforementioned 
schedules translate into an equivalent total dose of 126 Gy2 
and 60 Gy2, respectively. An escalation to 5 × 9 Gy would gain 
another 11.25 Gy. Using another model described by Yaes & 
Maruyama [37], keeping the same α/β-value of 10 Gy, the bio-
logically effective doses of 151.2 Gy2 versus 72 Gy2 would re-
sult, respectively. 
Conclusion 
hfSRT of lung tumors using a dose-escalating schedule of five 
fractions with 7 Gy and 8 Gy was well tolerated. Dose escala-
tion will be continued.
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